CBChristian M. Becker

Christian M. Becker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian M. Becker has a total of 583 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The management of endometriosis in adolescents and young adults: a systematic review

    by Ursula Blyth, Luba Maslej, George Bennett, Carolyn Smith, Emma Evans, Pedro Melo, Katy Vincent, Krina T Zondervan, Stacey A Missmer, Christian M Becker

    STUDY QUESTION: What evidence-based strategies are used in the treatment of endometriosis-associated symptoms in adolescents and young adults? SUMMARY ANSWER: The use of hormonal therapies and surgery was associated with improvements in pain symptoms in most studies; however, the certainty of evidence was very low, meaning that the true impact of these treatments remains uncertain. WHAT IS KNOWN ALREADY: Endometriosis is a chronic condition estimated to affect 1 in 10 women, with symptoms commonly present during adolescence. Current management strategies for endometriosis include analgesia, hormonal suppression, and surgery, as well as non-pharmacological measures. STUDY DESIGN, SIZE, DURATION: This is a systematic review of the literature. Six databases (CINAHL, Cochrane Central Database of Controlled Trials, EMBASE, MEDLINE, PsychInfo, and Web of Science Core Collection) were searched from inception to May 2026. Search terms were related to endometriosis combined with terms regarding management and the adolescent age group. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible studies included participants aged under 24 years with endometriosis and reported on outcomes in the management of endometriosis-associated symptoms. Only studies with full texts or data available in English were included. Screening and data extraction were performed independently and in duplicate by two authors. Key outcomes included pain, quality of life, recurrence, and side effects. Data were reported narratively. Risk of bias was assessed according to study design (ROB2, NOS, and JBI tools) and quality of evidence with the GRADE system. MAIN RESULTS AND THE ROLE OF CHANCE: The search identified 14 376 records, of which 333 full texts were assessed for eligibility, and 23 studies, with a combined total of 1561 participants, were included. There were two randomised controlled trials, one single-arm open-label interventional study, eleven cohort studies, and nine case series. Five studies investigated hormonal treatments, one other study assessed other pharmacological treatments, sixteen studies assessed surgical management with or without hormonal treatment, and one study investigated non-pharmacological treatments. Most studies reported improvements in pain symptoms; however, there was heterogeneity in study design, length of follow-up, and outcome measures. LIMITATIONS, REASONS FOR CAUTION: There is limited evidence in this age group. Most studies had a moderate risk of bias, and the certainty of evidence was very low. WIDER IMPLICATIONS OF THE FINDINGS: The very low certainty of evidence limits the ability to draw inferences from the data. More high-quality research is essential to understand the effectiveness of current treatments and identify how they should be tailored for this age group. FUNDING: No specific external or departmental funding was received for this systematic review. DISCLOSURES: C.M.B. declares research grants from US DoD, NIH, EU Horizon 2020, Bayer AG, Aspira Ltd, Exeltis Ltd, Proteomics Inc, and Serac Healthcare Ltd, and consulting fees from Gedeon Richter, Theramex, Gesynta, and Roche (all paid to institution). C.M.B. is Chair of the ESHRE Endometriosis Guideline Group and a member of the NICE Endometriosis Guideline Group (unpaid). S.A.M. declares research grants (paid to institution) from AbbVie and the Marriot Family Foundations, received honoraria from the University of Kansas Medical Center and received travel support from LIDEA Registry, Taiwan Endometriosis Society, SEUD, Japan Endometriosis Society, NASEM, Endometriosis Foundation of America, Gedeon Richter, WES, New York Academy of Sciences, and Asian Conference on Endometriosis. S.A.M. is Field Chief Editor for Frontiers in Reproductive Health (personal fee) and is an advisory board member for the LIDEA Registry (personal fee) and has unpaid roles with Human Reproduction Statistical Advisory Board and the NextGen Jane Advisory Board, the Society for Women’s Health Research, WERF, WES, ASRM, and ESHRE. K.V. reports research grants from the NIHR, NIH, UKRI, Medical Research Foundation, and EU IMI-2, consulting fees from Gesynta and Reckitts, and speakers’ fees from Reckitts, Organon, Gedeon Richter, and Eli Lilly (all payments to institution). K.V. is a member of the Medical Advisory Panel of Endometriosis UK (unpaid). K.T.Z. declares research grants from the Gates Foundation, US DoD, NIH, EU Horizon 2020, Bayer AG, Aspira Ltd, Exeltis Ltd, Proteomics Inc, and Serac Healthcare Ltd and consulting fees from Apikal Ltd, Gedeon Richter, Roche, and LIDEA, (all paid to institution), and speaker’s fees (paid to institution) from Rathlin Therapeutics and Camber Collective/Gates Foundation, received travel support for ESHRE 2025, SEUD 2024, EEC 2024, and LIDEA 2023, and is named on patent WO2024115891A1 relating to chronic pelvic pain treatment (NRG3), which is unrelated to the present manuscript. K.T.Z. is a board member of the World Endometriosis Foundation (unpaid). U.B., L.M., G.B., C.S., E.E., and P.M. declare no conflict of interest. Some of the above companies manufacture treatments discussed in this review. REGISTRATION NUMBER: CRD420251018467.

  • Open Access

    Iron homeostasis and endometriosis risk: Genetic evidence for a shared biological link

    by Veronika Denner, Christian M. Becker, Hal Drakesmith, Krina T. Zondervan, Sam Morris, Nilufer Rahmioglu

    STUDY QUESTION: Is genetic liability to endometriosis associated with iron homeostasis, and is this relationship potentially causal? SUMMARY ANSWER: Genetic evidence indicates that reduced systemic iron status is associated with increased risk of endometriosis, with evidence of 8 shared genome-wide significant loci and suggestive but inconsistent evidence for causal bidirectional effects. WHAT IS KNOWN ALREADY: Endometriosis is a chronic inflammatory condition associated with local iron accumulation within ectopic lesions and peritoneal cavity, resulting from retrograde menstruation and altered iron homeostasis. Epidemiological studies have suggested that women with endometriosis may exhibit reduced systemic iron stores compared to women without endometriosis, reflected by lower circulating ferritin concentrations, although findings have been inconsistent and may be confounded by menstrual blood loss and inflammation. As observational studies cannot distinguish causal relationships from secondary effects or residual confounding, the potential genetic basis linking iron homeostasis and endometriosis risk remains unclear. STUDY DESIGN, SIZE, DURATION: We performed genetic analyses using summary statistics from large-scale genome-wide association studies (GWAS) of endometriosis (overall and stage III/IV disease) and five iron biomarkers (serum iron, ferritin, total iron-binding capacity (TIBC), transferrin saturation, and hepcidin). Analyses included genome-wide genetic correlation using linkage disequilibrium score regression (LDSC), identification of shared genetic variants using multi-trait GWAS (MTAG) and bidirectional Mendelian randomisation to evaluate potential causal relationships. PARTICIPANTS/MATERIALS, SETTING, METHODS: Iron biomarker summary statistics came from a six-cohort GWAS meta-analysis (HUNT, MGI, SardiNIA, deCODE, Interval, DBDS; N up to 257,953) of blood-derived serum iron, ferritin, transferrin saturation and TIBC (Moksnes et al., 2022). Endometriosis summary statistics came from a 24-study GWAS meta-analysis (60,674 cases, 701,926 controls; European and East Asian ancestry), 12 of which had surgically confirmed cases (Rahmioglu et al., 2023). Genome-wide genetic correlations between iron biomarkers and endometriosis (overall and stage III/IV disease) were estimated using linkage disequilibrium score regression (LDSC), based on summary statistics aligned to the GRCh37 reference genome and restricted to HapMap3 variants. Multi-trait GWAS (MTAG) was applied to each iron biomarker jointly with endometriosis to enhance discovery of genetic loci. Shared loci were functionally annotated using reproductive and iron related tissues from GTEx v8 and blood from eQTLGen expression quantitative trait loci (eQTL) data. Bidirectional Mendelian randomisation (MR) analyses were performed using genome-wide significant variants across multiple clumping thresholds, with inverse-variance weighting (IVW) as the primary method and sensitivity analyses including weighted median, MR-Egger and MR-PRESSO. MAIN RESULTS AND THE ROLE OF CHANCE: Genetic correlation analyses suggested that a genetic predisposition to endometriosis is associated with a profile of lower systemic iron availability. Specifically, genetic liability to endometriosis was associated with higher total iron-binding capacity (TIBC; rg=0.16, p=4x10 -4 ), together with lower transferrin saturation (rg=-0.16, p=0.006) and lower ferritin levels (rg= -0.10, p=0.022), findings that are consistent with reduced iron stores. MTAG identified eight additional genome-wide significant loci for endometriosis and eight loci shared with iron biomarkers, including regions implicating coagulation (F5), innate immune response (IL1A), reproductive biology (WNT4), and immune and vascular pathways (e.g. ABO, STAT6). Mendelian randomisation analyses provided limited and inconsistent evidence for a causal relationship between iron status and endometriosis. Although the inverse-variance weighted (IVW) model showed nominal associations between higher ferritin levels and a lower risk of endometriosis (OR = 0.85, 95% CI 0.76–0.94; p = 0.002), and between genetic liability to endometriosis and higher TIBC (OR = 1.02, 95% CI 1.01–1.04; p = 0.006), these findings were not consistently supported by sensitivity analyses. MR-PRESSO identified a small number of pleiotropic variants, but their removal did not materially alter the results. LIMITATIONS, REASONS FOR CAUTION: Iron biomarker GWAS included males and females, potentially obscuring female-specific effects. Dataset availability restricted analyses to European ancestry, limiting applicability to other populations, and to overall and stage III/IV endometriosis, precluding assessment of other disease subtypes. Heterogeneity across SNP instruments, reflected by Cochran’s Q statistics, reduced the precision of Mendelian randomisation estimates. Moreover, the genetic instruments explained only between approximately 1.0% and 18.8% of variance in the iron biomarkers, depending on the clumping threshold, which may have limited power to detect causal effects. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that endometriosis is genetically associated with reduced systemic iron availability and altered iron homeostasis. Thus, lower systemic iron status observed in women with endometriosis may not be explained solely by menstrual blood loss or dietary factors, but reflect an underlying genetic predisposition. Shared genetic loci implicate coagulation, ABO biology, and immune pathways as potential mechanisms linking iron metabolism and endometriosis. Although Mendelian randomisation did not provide consistent evidence for causality, these findings support a shared genetic architecture and warrant further investigation using female-specific GWAS, refined disease subtypes, and multi-omic approaches. Clinically, these findings suggest that low systemic iron status in women with endometriosis may reflect factors beyond established causes of iron deficiency, including an underlying genetic predisposition. STUDY FUNDING/COMPETING INTEREST(S): The research was supported by a three-month post-MSc fellowship (September to December 2025), awarded to V.D. by the Nuffield Department of Population Health. N.R. is a consultant for Endogene.bio, outside this submitted work. V.D. and S.M. declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.

  • Open Access

    Deep immune profiling of endometrial and peripheral blood cells in endometriosis

    by A Kisovar, M Buttenschoen, Q Obrigewitch, K Powell, P Klenerman, K Zondervan, C M Becker, I E Granne, J H Southcombe

    STUDY QUESTION: How is endometrial and systemic immunity modulated throughout the menstrual cycle and are there changes in women with endometriosis? SUMMARY ANSWER: Endometriosis is associated with reduced endometrial early natural killer (NK) cells and increased mucosal-associated invariant T (MAIT)-like CD8+ T cells, with cyclical variation. WHAT IS KNOWN ALREADY: The endometrial mucosa contains innate and adaptive immune cells that fluctuate across the menstrual cycle. Immune dysregulation is found in endometriosis, however few studies have broadly assessed endometrial immune single-cell proteome phenotypes. STUDY DESIGN, SIZE, DURATION: This observational cross-sectional immune phenotyping study included 40 participants (28 with surgically confirmed endometriosis and 12 controls). PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial and peripheral blood samples were analysed by spectral flow cytometry using a 36-parameter immune phenotyping panel and a 13-parameter MAIT-specific panel. Totals of 1 950 292 circulating and 1 023 215 endometrial immune cells were profiled. Full-thickness uterine biopsies (n = 3) underwent multiplex immunohistochemical imaging to assess spatial organization across the menstrual cycle. MAIN RESULTS AND THE ROLE OF CHANCE: Compared with controls, patients with endometriosis exhibited decreased endometrial early NK cells (P.adj = 0.006, log2FC = −1.369) and increased MAIT-like CD8+ T cells (CD161+CD8+CD3+) (P.adj = 0.033, log2FC = 1.415). The MAIT cells (CD161+Va7.2+CD3+) peaked during ovulation and the implantation window (P.adj < 0.05). Peripheral immunity also showed cyclical variation with increased early NK cells (P.adj = 0.001, log2FC = 1.052) and decreased effector CD4 T (P.adj = 0.002/log2FC = −2.010) and effector CD8 T cells (P.adj = 0.002, log2FC = −1.180) in the endometriosis group. LIMITATIONS, REASONS FOR CAUTION: The cytometric panel design was biased towards acquired immunity, and the endometriosis patient sample size prevented subtype analysis. WIDER IMPLICATIONS OF THE FINDINGS: MAIT cell dysregulation represents a novel feature of endometriosis, potentially contributing to subfertility and providing new avenues for therapeutic development. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Nuffield Department of Women’s and Reproductive Health, University of Oxford, and also supported from the University of Oxford Medical Sciences HIDI Internal Fund Award (0010398), Academy of Medical Science Award (SBF007\100078) and, British Society for Immunology Career Enhancing Grant. C.M.B. has a consultancy role with ObsEva, Theramex, Roche Diagnostics, Sumitovant, Gedeon Richter, Gesyntha, and they have Research Grants from Bayer, Gesyntha, and Serac Life Services. K.Z. is a Board member (non-remunerated) of the World Endometriosis Research Foundation. She has consultancy status with Roche Diagnostics and Gedeon Richter. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

  • Open Access

    Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study

    by Jacques Donnez, Christian M Becker, Felice Petraglia, Andrew W Horne, Sven Becker, Stefan P Renner, Francisco Carmona Herrera, Hugh S Taylor, Maciej Paszkowski, Elke Bestel, et al.

    STUDY QUESTION: Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months? SUMMARY ANSWER: Efficacy from this extension study complements the results of the main trial, by showing that linzagolix is effective at reducing endometriosis-associated pain for a majority of women. WHAT IS KNOWN ALREADY: In the pivotal EDELWEISS 3 randomized controlled trial, the efficacy and safety of 24 weeks of once-daily oral linzagolix (a GnRH antagonist) were reported in women with endometriosis-related pain. Risks of bone mineral density (BMD) loss and vasomotor symptoms were minimized in both groups. STUDY DESIGN, SIZE, DURATION: EDELWEISS 3 was a prospective, randomized, double-blind study. Subjects completing the 6-month treatment period in EDELWEISS 3 were invited to participate in the present extension study: EDELWEISS 6. Only subjects who had completed the full 6-month treatment course in the main study and who met the inclusion criteria were eligible for entry into the extension study. Among 486 patients who completed the 6-month study, 353 participated in the extension study from March 2020 to February 2023. The current extension study started at Month 6 of the main EDELWEISS 3 phase-3 trial. Upon the end of treatment in the extension study (6-month treatment period from Month 6 to Month 12), subjects entered a post-treatment follow-up period of 6 months. The current report describes outcomes from the extension treatment period (up to 12 months) and subsequent follow-up of 6 months with no investigational medicinal product. The co-primary endpoints were the reduction in dysmenorrhea and non-menstrual pelvic pain at Month 12. PARTICIPANTS/MATERIALS, SETTING, METHODS: Premenopausal women with moderate-to-severe endometriosis who previously completed the full 6-month treatment period in the main study and met the inclusion criteria were eligible for the extension study. All subjects (n = 353), whether given placebo or not in the main study, received either 75 mg linzagolix alone or 200 mg combined with hormonal add-back therapy (ABT) once daily for the additional 6 months, i.e. those who were given a placebo during the main study were randomized to either group and those who had received active treatment continued with the same treatment (placebo/75 mg linzagolix [n = 57], placebo/200 mg linzagolix plus ABT [n = 57], 75 mg linzagolix [n = 118], and 200 mg linzagolix plus ABT [n = 121]). Pain was measured daily on a verbal rating scale and recorded in an electronic diary. The trial was performed in clinics and university hospitals in the USA and Europe. MAIN RESULTS AND THE ROLE OF CHANCE: By Month 12, of the 353 women who were treated and analyzed, the proportion of subjects with a significant reduction in dysmenorrhea and stable or decreased use of analgesics was 55.9% in the 75 mg linzagolix group and 91.0% in the 200 mg+ABT linzagolix group. The proportion of subjects with a significant reduction in non-menstrual pelvic pain and stable or decreased use of analgesics was 59.5% in the 75 mg linzagolix group and 67.6% in the 200 mg+ABT linzagolix group. A steady reduction in mean daily dyschezia, dyspareunia, and overall pelvic pain scores was observed in both linzagolix groups from baseline to Month 12, with a more marked reduction in the 200 mg+ABT linzagolix group. Quality of life was assessed using the EHP-30 questionnaire. At Month 12, clear improvements (total score reductions) were observed in both linzagolix groups, with greater improvements in five out of five dimensions in the 200 mg+ABT linzagolix group. Changes in body mass index were minimal, with no clinically meaningful modifications from Month 6 to Month 12. Adverse events including hot flushes were encountered in fewer than 1% of subjects. During the off-treatment follow-up period of 6 months, some of the improvements were maintained for several months. LIMITATIONS, REASONS FOR CAUTION: Efficacy was originally compared between the linzagolix and placebo groups from the main study, however, it would have been useful to have results from comparative studies with estro-progestogens or progestogens, to ascertain whether a GnRH antagonist has significant benefits over traditional first-line medications. WIDER IMPLICATIONS OF THE FINDINGS: Linzagolix, when administered orally once daily at a dose of 200 mg in combination with ABT, offers an additional option for effective, safe, and well-tolerated medical treatments for endometriosis that can be proposed in cases of estro-progestogen or progestogen inefficacy, as it can be used for a longer term, improving quality of life and reducing the need for analgesics and opioids. The risks of bone mineral loss and vasomotor symptoms were minimized due to the ABT. The 75 mg dose alone could be suitable for chronic treatment of endometriosis-associated pain without the need for concomitant hormonal ABT and may offer an option for some women, although further research is needed to confirm this finding. STUDY FUNDING, COMPETING INTEREST(S): Funding for the EDELWEISS 6 study was provided by Geneva, Switzerland. Analysis of data was partially supported by ObsEva (Geneva, Switzerland), Theramex (London, UK), and Kissei (Japan). Grant 5/4/150/5 was awarded to M.-M.D. by the Fonds National de la Recherche Scientifique (FNRS). J.D. was a member of the scientific advisory board of ObsEva and Preglem until 2023 and reports consulting fees from ObsEva, Gedeon Richter, and Theramex. C.M.B. declares consulting fees (paid to University of Oxford) from Myovant for an advisory board and from Theramex; payment or honoraria (paid to University of Oxford) for talks at different meetings from [Theramex and Gedeon Richter]; support for attending meetings and/or travel (paid to University of Oxford) from [Gedeon Richter]; being a member of the independent data monitoring board for the EDELWEIS 3 trial and member of the...


  • Endometriosis lesion distribution by age at presentation: an international multicentre database study

    by Jonathan Lewin, Arvind Vashisht, Dean Langan, Katy Vincent, Ertan Saridogan, Christian M Becker, Martin Hirsch

    STUDY QUESTION: How does the frequency and location of endometriosis lesions observed at laparoscopy vary with patient age? SUMMARY ANSWER: We find that older patients have more deep lesions and ovarian endometriomas at laparoscopy, although this plateaus around 30 years of age. WHAT IS KNOWN ALREADY: The natural history and aetiology of endometriosis remain uncertain, with evidence of progression, spontaneous regression, and stable disease in various studies. STUDY DESIGN, SIZE, DURATION: Cross-sectional analysis of a prospectively collected surgical registry, including data from 104 accredited endometriosis centres across 7 countries, with 14 670 cases in total. PARTICIPANTS/MATERIALS, SETTING, METHODS: We analysed data from the British Society for Gynaecological Endoscopy (BSGE) endometriosis centres database, a multicentre international prospective cohort of patients undergoing surgery for deep endometriosis. We included all patients aged 10–55 years from 2009 to 2021. The change in lesion prevalence with age was modelled using three different logistic regression models—non-quadratic, quadratic, and segmented, adjusted for whether they had undergone endometriosis excision in the past. MAIN RESULTS AND THE ROLE OF CHANCE: We identified 14 670 cases from 104 centres across 7 countries. The mean age at the time of surgery was 35.9 years (SD 7.4). The odds of superficial endometriosis decreased linearly with age by 3% per year (adjusted odds ratio (aOR) 0.97, 95% CI 0.96–0.97, P < 0.001). The following increased before plateauing: bowel endometriosis increased by 7% per year (aOR 1.07, 95% CI 1.05–1.09, P < 0.001) until 32.9 years of age (95% CI 30.5–35.3); deep sidewall disease increased by 7% per year (aOR 1.07, 95% CI 1.05–1.09, P < 0.001) until 31.3 years (95% CI 29.2–33.5); and uterosacral disease increased by 4% per year (aOR 1.04, 95% CI 1.02–1.06, P < 0.001) until 33 years (95% CI 29.3–36.6). Deep bladder disease increased by 12% per year (aOR 1.12, 95% CI 1.04–1.22, P = 0.005) until 28.2 (95% CI 25.8–30.6) years, after which the odds decreased by 2% per year (aOR 0.98, 95% CI 0.97–1.00, P = 0.007). Ovarian endometrioma was best described by a quadratic model, with a starting increase in odds of endometrioma of 20% per year at 10 years (aOR 1.20, 95% CI 1.16–1.23, P < 0.001), and a peak prevalence at 40.9 years of age (95% CI 34.1–47.7, P < 0.001). The total number of sites affected by endometriosis increased by 0.12 sites per year (95% CI 0.10–0.14, P < 0.001) until 32.8 years of age, with no correlation with age after this point. LIMITATIONS, REASONS FOR CAUTION: This cross-sectional study only includes patients undergoing excision with pararectal dissection for the treatment of pain, so does not capture patients who do not undergo such surgery, including asymptomatic patients, and cannot provide data on potential disease progression on an individual level. WIDER IMPLICATIONS OF THE FINDINGS: This study supports existing evidence suggesting that older patients with endometriosis have more deep nodules and endometriomas and less superficial disease. STUDY FUNDING/COMPETING INTEREST(S): No funding was provided for this study. K.V. reports consulting fees from Eli Lilly, Gedeon Richter, Gesynta, and Rickett (all paid to institution); speakers’ fees from Gedeon Richter and Reckitt (both paid to institution); membership of the Medical Advisory Panel of Endometriosis UK (unpaid); past presidency of the International Association for the Study of Pain (IASP) Special Interest Group (SIG) on Abdominal and Pelvic Pain (unpaid). TRIAL REGISTRATION NUMBER: N/A.

  • Open Access

    Human Endometriotic Lesion‐Derived Small Extracellular Vesicles Impair Macrophage Function in the Peritoneal Microenvironment

    by Yifan Wang, Zhixing Jin, Abigail Freeman Blatchford, Banayot Hosh, Malak Amer, Ayazhan Akhatova, Krina Zondervan, Erin Greaves, Rebecca Dragovic, Christian M Becker, et al.

    Endometriosis (EM) is a chronic inflammatory disease that affects ∼10% of women during reproductive age. It is characterised by ectopic (ECT) growth of endometrial‐like tissue mainly in the pelvic cavity. Small extracellular vesicles (sEVs) mediate cellular interactions, but their function remains poorly understood in the pathogenesis of EM. 3D endometrial epithelial organoids (EEOs) from ECT lesions and eutopic (EUT) endometrium from EM patients and controls were established to investigate sEVs. Multiplex bead‐based flow cytometry revealed CD133/1 and EpCAM as dominant markers on EEO‐sEVs, with ECT EEO‐sEVs showing upregulation of CD44, CD29 and downregulation of EpCAM compared to EUT EEO‐sEVs. Peritoneal fluid (PF)‐sEVs displayed high and correlated CD133/1 and EpCAM expression, indicating a major contribution from endometrial epithelial (EE) cells, alongside sEVs of lymphocyte and endothelial origin. Functionally, both ECT EEO‐sEVs and PF‐sEVs from EM patients significantly suppressed macrophage phagocytosis, as assessed by pH‐sensitive fluorescent bioparticles. The effect was reversed by CD47 blockade. The coexpression of CD47 with CD133/1 and EpCAM on PF‐sEVs indicates the involvement of EE cell‐derived sEVs in CD47/SIRP‐α mediated suppression. This study provides the first thorough characterisation of EE‐derived sEVs utilising EEO models in EM and demonstrates their potential immunomodulatory role in the peritoneal microenvironment via CD47/SIRP‐α signalling.


  • Open Access

    Embryo secretome regulation of the endometrial epithelial transcriptome: development of a model to test for embryo viability

    by Zhixing Jin, Yifan Wang, Abigail Freeman Blatchford, Helena Rodriguez-Caro, Luyao Wang, Christian M Becker, Pedro Melo, Tim Child, Rebecca Dragovic, Ingrid Granne, et al.

    The aim of this study was to develop an advanced in vitro model of human endometrium using single-cell-derived endometrial epithelial organoids, enabling the study of embryo secretome–endometrial crosstalk at the maternal–fetal interface. Single-cell-derived organoids generated from endometrial tissue of a parous 39-year-old woman recapitulated hormone-responsive decidualization, as demonstrated by expression of SPP1 and acetyl-α-tubulin. When cultured in embryo culture media, organoid viability was maintained with no cytotoxicity, but proliferation was suppressed, likely due to the lower concentrations of the required factors in organoid growth media. Organoids were stimulated with culture supernatants from morphologically good-quality embryos with known pregnancy outcomes (live birth (n = 4) vs no pregnancy (n = 4)). Transcriptomic profiling (RNA-sequencing) revealed that 32 genes were differentially expressed (DEGs) in organoids exposed to the culture supernatants from live-birth embryos versus non-pregnant outcomes: 24 upregulated and 8 downregulated. These DEGs were enriched for biological processes related to cell motility and cytoskeletal dynamics. In conclusion, soluble factors secreted by human blastocysts achieving live birth selectively modulate the endometrial epithelial transcriptome, enhancing pathways involved in cytoskeletal remodeling and immune modulation. This embryo-directed remodeling likely facilitates endometrial receptivity for successful implantation to occur. Our organoid model provides a robust platform for further investigating implantation failure.


  • Open Access

    Long Term Reproductive Health Outcomes in Women Treated for Osteosarcoma During Childhood: A Systematic Review

    by Ursula Blyth, Shehani Alwis, Emerald Win Oo, Pedro Melo, Suzannah A. Williams, Sheila Lane, Christian M. Becker


  • Open Access

    Women with chronic pelvic pain can be stratified using multimodal assessment

    by Lysia Demetriou, Lydia Coxon, Emma Evans, Kevin Kuan, Danielle Perro, Kirsten Parsons, Emily Tan, Ana Charrua, Joana Ferreira-Gomes, Pedro Abreu Mendes, et al.

    Chronic pelvic pain (CPP) is a common and burdensome symptom in women yet current clinical management frequently leaves many with persistent pain. The Translational Research in Pelvic Pain (TRiPP) project adopts a pain-focused strategy, aiming to better phenotype CPP through multimodal assessment. Here, we integrated questionnaire, physiological, and biological data to (1) determine whether perturbations in the function of pain-relevant systems in women with CPP can be demonstrated and (2) explore whether these data can stratify women with CPP into meaningful subgroups, independent of diagnostic group. Participants included 108 women, aged 18 to 50 years, with CPP including endometriosis-associated pain (EAP), bladder pain syndrome (BPS), comorbid EAP and BPS, and pelvic pain with no underlying pathology alongside 50 pain-free controls. Analyses were conducted in 3 stages: (1) group comparisons, (2) latent profile analysis to identify CPP subgroups, and (3) clinical characterization of resulting clusters. Compared with controls, CPP participants reported significantly greater fatigue, poorer sleep, higher anxiety, depression, pain catastrophising, and more childhood trauma ( P < 0.01). However, no significant differences were observed in physiological measures. Latent profile analysis revealed 3 distinct CPP subgroups, differentiated by questionnaires rather than physiological measures. Cluster 1 represents a group with predominantly higher-impact pain compared with others, that may be associated with nociplastic mechanisms. These findings support alternative approaches to stratification of CPP separate from standard diagnostic groupings. The role of questionnaire measures in this stratification facilitates translation to clinical settings; however, further work is required to determine whether differing therapeutic approaches are appropriate for each cluster.


  • Open Access

    The role of pre-operative gonadotrophin-releasing hormone agonists (GnRHa) on pain, bowel and bladder symptoms in rectovaginal/colorectal endometriosis surgery: a multicenter cohort study

    by Munazzah Rafique, Christian Becker, Jonathan Lewin, Arvind Vashisht, Ertan Sarıdoğan, Martin Hirsch

    The efficacy of medical and surgical treatment of endometriosis-associated pain is a source of ongoing controversy. There is a lack of evidence about gonadotropin-releasing hormone agonists (GnRHa) use on long-term pain control, bladder and bowel symptoms for patients having surgery for deep rectovaginal/colorectal endometriosis. To assess the effect of preoperative GnRHa (pre-GnRHa) use on pain, bowel and bladder symptoms for patients undergoing surgery for deep rectovaginal/colorectal endometriosis. The study evaluated data from the British Society for Gynaecological Endoscopy database, a large international multicentre prospective cohort of patients who underwent deep rectovaginal/colorectal endometriosis surgery between 2009-2021. We included 9433 patients from 101 accredited endometriosis centres. Multivariable logistic regression analysis was used to evaluate the association between pre-GnRHa use and postoperative pain, bowel and bladder symptoms at different time points, controlling for confounders like patient age, body mass index, smoking status, and hysterectomy. Rate of cyclical and non-cyclical pelvic and menstrual pain, bowel and bladder symptoms. The mean age of the patients was 36 years (18-55). Pre-GnRHa use was associated with significant postoperative improvement in premenstrual pain [odds ratio (OR): 0.30, 95% confidence interval (CI): -0.57 - -0.034, P=0.02*], menstrual pain (OR: 0.41/10, 95% CI: -0.7 - -0.13, P=P=0.021*) and lower backache (OR: 0.30, 95% CI: -0.532 - -0.087, P=0.006*) up to 12 months postoperatively. Moreover, bladder pain was significantly reduced in the pre-GnRHa group at 12 months (OR: 0.24, 95% CI: -0.451 - -0.039, P=0.01*). Significant improvements were observed in bowel symptoms including frequent bowel movements (OR: 0.10, 95% CI: -0.194 - -0.012, P=0.02*), incomplete emptying sensation (OR: 0.10, 95% CI: -0.196 - -0.023, P=0.01*), cyclical dyschezia (OR: 0.43, 95% CI: -0.724 - -0.142, P=0.003*) and non-cyclical dyschezia (OR: 0.28, 95% CI: -0.504 - -0.075, P=0.008*) up to 12 months. Pre-GnRHa use is associated with a significant reduction in postoperative menstrual pain and non-menstrual pain as well as improved bowel and bladder symptoms lasting up to two years. It is also valuable to improve the quality of life for patients undergoing surgery for deep rectovaginal/colorectal endometriosis. This is the largest prospective international study evaluating pre-GnRHa use in deep rectovaginal/colorectal endometriosis surgery. It provides evidence supporting the role of pre-GnRHa as an adjuvant to surgical treatment, to reduce postoperative pain and improve bowel and bladder function.